申请人:Novo Nordisk A/S
公开号:US05559106A1
公开(公告)日:1996-09-24
Quinoxaline compounds of the general formula ##STR1## wherein R.sup.1 is COX', POX'X" or alkyl substituted with COX' or POX'X", and X' and X" independently are hydroxy or alkoxy, and R.sup.6, R.sup.7, R.sup.8 and R.sup.9 independently are hydrogen, alkyl, halogen, NH.sub.2, NO.sub.2, CN, CF.sub.3, SO.sub.2 NY'Y" or COZ' wherein Z' is NY'Y" or alkyl and Y' and Y" independently are hydrogen or alkyl, triazolyl, imidazolyl, imidazolyl substituted with phenyl or alkyl, or R.sup.6 and R.sup.7, or R.sup.8 and R.sup.9, together form a further fused ring, are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters.
喹啉化合物的一般式为##STR1##其中R.sup.1为COX',POX'X"或被COX'或POX'X"取代的烷基,X'和X"独立地为羟基或烷氧基,而R.sup.6、R.sup.7、R.sup.8和R.sup.9独立地为氢、烷基、卤素、NH.sub.2、NO.sub.2、CN、CF.sub.3、SO.sub.2NY'Y"或COZ',其中Z'为NY'Y"或烷基,而Y'和Y"独立地为氢或烷基,三唑基,咪唑基,咪唑基取代苯基或烷基,或R.sup.6和R.sup.7,或R.sup.8和R.sup.9,共同形成进一步融合环,在治疗由兴奋性神经递质过度活跃引起的症状中很有用。